Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overweight: full-pipeline trial registry
50 of 198 indexed Overweight trials are currently recruiting.
Corpus placement: #52 of 28,707 conditions by registered trial count.
198 US clinical trials · 50 currently recruiting · #52 of 28,707 conditions by registered trial count
Overweight: 198 US clinical trials tracked, 50 recruiting.
Overweight is the subject of 198 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 37 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 37 of these trials.
Enrollment posture brief
Registry condition overweight
OPEN 50 | RECR 25% | LATE 37 | EARLY 46 | RANK #52 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Overweight lists 50 open slots (25% of 198 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overweight on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overweight is recruiting below its size-band peers.
50 of 198 indexed trials (25.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Overweight research.
Eli Lilly and Company accounts for 37 of 198 trials (18.7%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Overweight enrolment sits around 120 participants.
Median target enrolment is 120 among the 198 trials that report a genuine target (sentinel values excluded). 89 of those (44.9%) plan for fewer than 100 participants.
-
Overweight research is mostly interventional.
182 interventional and 16 observational studies make up this index (91.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
198 total, page 2 of 4
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Brigham and Women's Hospital
NCT07417618
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company
NCT05556512
Partnerships for Reducing Overweight and Obesity with Patient-Centered Strategies 2.0
Brigham and Women's Hospital
NCT05553925
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT05869903
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company
NCT05803421
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company
NCT05929066
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company
NCT05929079
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company
NCT06914895
Biological Sample Repository for Gastrointestinal Disorders
Pichamol Jirapinyo, MD, MPH
NCT05874726
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company
NCT06962280
TOTAL: A Multisite RCT
VA Office of Research and Development
NCT05346575
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT06047548
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company
NCT06603571
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Amgen
NCT07226778
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S
NCT07220759
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Eli Lilly and Company
NCT06606106
NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers
New York University
NCT05461495
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S
NCT07220642
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company
NCT06683508
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Hoffmann-La Roche
NCT06965413
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company
NCT06643728
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
WW International
NCT06605703
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma
NCT06926842
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Verdiva Bio Dev Limited
NCT07281937
Promotion of Weight Management
VA Office of Research and Development
NCT04131647
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT06075667
Taldefgrobep Alfa in Adults With Overweight and Obesity
Biohaven Therapeutics
NCT07281495
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
NCT05536804
A Study of Time Restricted Eating in Obese Adults
Mayo Clinic
NCT05660291
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
NCT06703021
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
Amgen
NCT07229157
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
Massachusetts General Hospital
NCT05774665
Piloting a Patient Navigator Program for Weight Loss
Drexel University
NCT06972381
A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity
Novo Nordisk A/S
NCT06577766
Study to Evaluate the Efficacy of an Avocado Dietary Supplement
SP Nutraceuticals
NCT07354308
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
M.D. Anderson Cancer Center
NCT03546972
The Effects of Almond Consumption on Functional Performance and Activity in Overweight Active Older Adults
Florida State University
NCT04778371
Variety of Physical Activity in Normal to Overweight Adults Who Are Regularly Active
The University of Tennessee, Knoxville
NCT02149147
Olive Oil Polyphenols and Cardiovascular Health Biomarkers
University of California, Davis
NCT04149288
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
Joslin Diabetes Center
NCT03860558
Monounsaturated Fatty Acid Supplementation for Overweight and Obese Individuals With Prediabetes
Brigham and Women's Hospital
NCT05560971
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
AdventHealth Translational Research Institute
NCT01745471
Study of the Carbon Dioxide Treatment for Fat Reduction
Northwestern University
NCT00974415
Family-Based Treatment for Type 1 Diabetes
State University of New York at Buffalo
NCT05756361
Enhancing Mental and Physical Health of Women Veterans
VA Office of Research and Development
NCT05050266
Mass in Motion Kids in the Clinical Setting
Massachusetts General Hospital
NCT02110615
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
Novo Nordisk A/S
NCT04972721
Electronic Tools to Assist With Identification of and Counseling for Overweight Patients
Northwestern University
NCT00973661
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT05872620
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Novo Nordisk A/S
NCT03552757
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 25 |
| Phase 3 | 36 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Overweight records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overweight trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overweight page
198 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Overweight trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Overweight trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overweight condition card totals 198 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.